Go Pro
Evan David Seigerman

Evan David Seigerman Analyst Performance

BioPharma Analyst at BMO Capital Markets

Evan David Seigerman is a stock analyst at BMO Capital Markets in the healthcare sector, covering 22 publicly traded companies. Over the past year, Evan David Seigerman has issued 45 stock ratings, including buy and hold recommendations. While full access to Evan David Seigerman's proprietary MarketBeat Analyst Ranking is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights Evan David Seigerman's coverage history, rating activity, and performance tendencies - helping individual investors make more informed trading decisions.

Analyst Rankings, Coverage, and Performance Statistics

Average Return
00.00% 12-Month ROI
Success Rate
00.00% Profitable Ratings
Total Ratings
82 Last 4 Years
Buy Recommendations
63.64% 49 Buy Ratings
Companies Covered
22 Unique Companies

Ratings Distribution

RatingPercentageCount
Strong Buy0.0%0 ratings
Buy63.6%49 ratings
Hold31.2%24 ratings
Sell5.2%4 ratings

Out of 77 total stock ratings issued by Evan David Seigerman at BMO Capital Markets, the majority (63.6%) have been Buy recommendations, followed by 31.2% Hold and 5.2% Sell.

Exchange Coverage

ExchangePercentageCount
NASDAQ
77.3% of companies on NASDAQ
17 companies
NYSE
22.7% of companies on NYSE
5 companies

Evan David Seigerman, an analyst at BMO Capital Markets, currently covers 22 companies listed on NASDAQ and NYSE, with the majority traded on NASDAQ.

Coverage Focus

Sector IconSectorPercentage
Healthcare
22 companies
100.0%

Evan David Seigerman of BMO Capital Markets specializes in stock coverage within the Healthcare sector.

Coverage Industries

IndustryPercentage
BIOTECHNOLOGY
15 companies
68.2%
PHARMACEUTICALS
7 companies
31.8%

About Evan David Seigerman

Evan is a Managing Director and Senior Research Analyst at BMO Capital Markets covering Biotechnology (Large and SMid Cap) and US Major Pharmaceuticals. His responsibilities also include leading the therapeutics research effort at BMO, shaping strategy and growing impact of the broader franchise. Prior to joining BMO, Evan was a senior research analyst at Credit Suisse, also covering Biotechnology. He started his Wall Street Career at Deutsche Bank and later was on the #2 Institutional Investor ranked Biopharma team at Barclays. Before equity research, Evan was a strategy consultant for Major Pharma and Biotechnology clients. Recently, Evan was named a Rising Star of Equity Research by Business Insider and is consistently recognized by investors as a leading voice in the biotechnology space. He has been featured in countless media outlets, including CNBC, PBS News Hour, BNN Canada, The Wall Street Journal, Barron’s, The Economist, Kiplinger’s Personal Finance, The New York Times, and industry trade publications. Evan holds a BBA in Finance and Accounting and BA in Spanish, both from the University of Michigan.

Evan David Seigerman's Ratings History at BMO Capital Markets

Recommendation ROI is the percentage between the price on the Report Date to the price 12 months after the report date.
Available with a MarketBeat All Access Subscription
12-Month ROIUpgrade to All Access to use the All ROI Filter
CompanyReport DateActionReport Date Price12-Month
Price Target
Rating12-Month
Price & ROI
Details
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
9/1/2026Upgrade$1,173.63Buy
Incyte Corporation stock logo
INCY
Incyte
9/1/2026Reiterated Rating$123.22Market Perform
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
8/20/2026Boost Price Target$151.13$170.00Outperform
Amgen Inc. stock logo
AMGN
Amgen
8/5/2026Boost Price Target$390.63$450.00Outperform
Incyte Corporation stock logo
INCY
Incyte
7/29/2026Boost Price Target$128.32$130.00Market Perform
ACADIA Pharmaceuticals Inc. stock logo
ACAD
ACADIA Pharmaceuticals
7/21/2026Boost Price Target$25.09$36.00Outperform
Pfizer Inc. stock logo
PFE
Pfizer
7/13/2026Lower Price Target$24.22$30.00Outperform
Neurocrine Biosciences, Inc. stock logo
NBIX
Neurocrine Biosciences
7/13/2026Boost Price Target$177.11$170.00Market Perform
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
7/13/2026Boost Price Target$123.72$142.00Outperform
Incyte Corporation stock logo
INCY
Incyte
7/13/2026Boost Price Target$116.71$112.00Market Perform
AbbVie Inc. stock logo
ABBV
AbbVie
7/13/2026Boost Price Target$248.00$300.00Outperform
Pfizer Inc. stock logo
PFE
Pfizer
6/23/2026Reiterated Rating$24.86Outperform
Incyte Corporation stock logo
INCY
Incyte
6/22/2026Upgrade$98.22$94.00Market Perform
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
5/18/2026Lower Price Target$628.80$730.00Outperform
Structure Therapeutics Inc. Sponsored ADR stock logo
GPCR
Structure Therapeutics
3/17/2026Set Price Target$55.92$145.00Outperform
Pfizer Inc. stock logo
PFE
Pfizer
3/9/2026Reiterated Rating$26.71$30.00Outperform
AbbVie Inc. stock logo
ABBV
AbbVie
3/9/2026Reiterated Rating$223.71Outperform
Disc Medicine, Inc. stock logo
IRON
Disc Medicine
2/17/2026Lower Price Target$55.99$100.00Outperform
Neurocrine Biosciences, Inc. stock logo
NBIX
Neurocrine Biosciences
2/12/2026Lower Price Target$125.89$140.00Market Perform
Biogen Inc. stock logo
BIIB
Biogen
2/6/2026Boost Price Target$201.69$196.00Market Perform
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
2/5/2026Reiterated Rating$44.37Market Perform
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
2/5/2026Set Price Target$47.18$45.00
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
2/5/2026Reiterated Rating$1,107.13$1,300.00Outperform
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
1/26/2026Set Price Target$63.60$57.00
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
1/26/2026Boost Price Target$135.93$150.00Outperform
AbbVie Inc. stock logo
ABBV
AbbVie
1/15/2026Reiterated Rating$217.78$258.00Outperform
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
1/14/2026Reiterated Rating$59.57Market Perform
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
1/14/2026Reiterated Rating$1,066.49Outperform
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
1/13/2026Reiterated Rating$123.67Outperform
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
12/23/2025Reiterated Rating$52.07Market Perform
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
12/18/2025Upgrade$99.19$130.00Outperform
Terns Pharmaceuticals, Inc. stock logo
TERN
Terns Pharmaceuticals
12/9/2025Boost Price Target$40.23$54.00Outperform
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
12/4/2025Set Price Target$1,033.00$1,200.00
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
12/4/2025Boost Price Target$723.67$850.00Outperform
Amgen Inc. stock logo
AMGN
Amgen
12/3/2025Boost Price Target$338.36$372.00Outperform
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
12/2/2025Boost Price Target$1,059.14$1,100.00Outperform
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
11/25/2025Set Price Target$126.99$135.00
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
11/25/2025Lower Price Target$44.99$46.00Market Perform
Terns Pharmaceuticals, Inc. stock logo
TERN
Terns Pharmaceuticals
11/18/2025Boost Price Target$26.82$30.00Outperform
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
11/17/2025Reiterated Rating$48.58Market Perform
Congress Just Opened the Floodgates (Ad)

The House passed the Digital Asset Market Clarity Act 294 to 134, creating the most comprehensive financial technology framework in US history. JPMorgan, Citi, Bank of America and Wells Fargo are building a shared next generation payment network targeting 2027, and the DTCC just completed its first live production trades on the new system. Senior analyst Andy Howard breaks down the asset at the center of this shift in a free report.tc pixel

Get the free report before the new financial grid launches this fall.
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
11/6/2025Boost Price Target$927.48$1,100.00Outperform
Terns Pharmaceuticals, Inc. stock logo
TERN
Terns Pharmaceuticals
11/3/2025Boost Price Target$14.03$22.00Outperform
Merus N.V. stock logo
MRUS
Merus
10/31/2025Reiterated Rating$95.05$97.00Market Perform
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
10/14/2025Reiterated Rating$57.51$55.00Market Perform
AbbVie Inc. stock logo
ABBV
AbbVie
9/12/2025Boost Price Target$220.09$240.00Outperform
Vertex Pharmaceuticals Incorporated stock logo
VRTX
Vertex Pharmaceuticals
8/5/2025Set Price Target$472.27$530.00Outperform
Incyte Corporation stock logo
INCY
Incyte
7/30/2025Reiterated Rating$78.05$60.00Underperform
Replimune Group, Inc. stock logo
REPL
Replimune Group
7/23/2025Downgrade$2.81$2.00Underperform
Neurogene Inc. stock logo
NGNE
Neurogene
6/12/2025Reiterated Rating$21.56$26.00Outperform
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
6/2/2025Lower Price Target$489.01$600.00Outperform
Merus N.V. stock logo
MRUS
Merus
5/23/2025Set Price Target$54.31$110.00Outperform
ACADIA Pharmaceuticals Inc. stock logo
ACAD
ACADIA Pharmaceuticals
5/19/2025Boost Price Target$21.94$28.00Outperform
Disc Medicine, Inc. stock logo
IRON
Disc Medicine
5/12/2025Boost Price Target$47.07$120.00Outperform
Neurocrine Biosciences, Inc. stock logo
NBIX
Neurocrine Biosciences
5/6/2025Boost Price Target$125.03$115.00Market Perform
Arvinas, Inc. stock logo
ARVN
Arvinas
5/5/2025Lower Price Target$7.72$10.00Outperform
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
4/30/2025Lower Price Target$581.07$800.00Outperform
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
4/17/2025Reiterated Rating$62.88$64.00Market Perform
Biogen Inc. stock logo
BIIB
Biogen
2/13/2025Lower Price Target$137.21$139.00Market Perform
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
2/12/2025Boost Price Target$103.85$115.00Outperform
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
2/5/2025Lower Price Target$88.93$96.00Market Perform
AbbVie Inc. stock logo
ABBV
AbbVie
2/3/2025Boost Price Target$183.90$215.00Outperform
Vertex Pharmaceuticals Incorporated stock logo
VRTX
Vertex Pharmaceuticals
1/31/2025Set Price Target$484.24$545.00
Replimune Group, Inc. stock logo
REPL
Replimune Group
1/22/2025Boost Price Target$13.20$27.00Outperform
Biogen Inc. stock logo
BIIB
Biogen
12/20/2024Downgrade$147.39$164.00Market Perform
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
12/20/2024Downgrade$99.52$105.00Market Perform
Neurogene Inc. stock logo
NGNE
Neurogene
11/20/2024Lower Price Target$17.40$45.00Outperform
Neurogene Inc. stock logo
NGNE
Neurogene
11/12/2024Lower Price Target$40.19$60.00Outperform
Incyte Corporation stock logo
INCY
Incyte
10/30/2024Reiterated Rating$72.99$52.00Underperform